Literature DB >> 24480222

Prognostic role and significance of paraneoplastic syndromes in hepatocellular carcinoma.

Qiang Qu1, Shaobin Wang, Shuguang Chen, Li Zhou, Jing-An Rui.   

Abstract

Patients with hepatocellular carcinoma (HCC) may develop paraneoplastic syndromes in the clinical course. These syndromes include hypercholesterolemia, hypoglycemia, hypercalcemia, and erythrocytosis, among others. This study was designed to assess the role of prognostic influence of paraneoplastic syndromes in patients with HCC. In a cohort of 175 patients with HCC patients, we compared the clinical features of patients with HCC with or without paraneoplastic syndromes. In addition, survival rates of patients with individual paraneoplastic syndromes and those without were also evaluated. Moreover, factors independently predicting prognosis among patients with HCC with or without paraneoplastic syndromes were analyzed. Among 175 patients with HCC, 54 patients presented paraneoplastic syndromes, and the prevalence was 30.9 per cent. There was no difference of clinical characteristics between patients with HCC with and without paraneoplastic syndromes on diagnosis. However, the patients with paraneoplastic syndromes had a significantly less survival rate comparing with those without during a 5-year follow-up. Cox regression analysis demonstrated that high Child-Pugh grade, large tumor size, portal vein tumor thrombosis, and distant metastasis were all independent unfavorable prognostic factors for survival of patients with HCC. Paraneoplastic syndromes as independent risk factors play a significant role in the progress of HCC and lead to poor prognosis in patients with HCC.

Entities:  

Mesh:

Year:  2014        PMID: 24480222

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  8 in total

1.  Hepatocellular Carcinoma Without Cirrhosis Presenting With Hypercalcemia: Case Report and Literature Review.

Authors:  Neil B Newman; Salma K Jabbour; Jane Date C Hon; Joseph J Berman; Deen Malik; Darren Carpizo; Rebecca A Moss
Journal:  J Clin Exp Hepatol       Date:  2015-04-18

2.  Refractory Hypoglycemia Presenting as First Manifestation of Advanced Hepatocellular Carcinoma.

Authors:  Mithun Sharma; Duvurru Nageshwar Reddy; Tan Chee Kiat
Journal:  ACG Case Rep J       Date:  2014-10-10

Review 3.  Dermatomyositis Induced by Hepatitis B Virus-related Hepatocellular Carcinoma: A Case Report and Review of the Literature.

Authors:  Jen-Wei Chou; Yin-Lan Lin; Ken-Sheng Cheng; Po-Yuan Wu; Teressa Reanne Ju
Journal:  Intern Med       Date:  2017-07-15       Impact factor: 1.271

4.  A Case of Humoral Hypercalcemia of Malignancy Secondary to Hepatocellular Carcinoma with Fulminant Clinical Course.

Authors:  Pamela Castro-Camero; Bumsoo Park; Amit Gupta; Raghavendra Vemulapalli; Maria Shreve
Journal:  Spartan Med Res J       Date:  2019-07-01

5.  PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma.

Authors:  Shi-Zhe Zhang; Xiao-Dong Zhu; Long-Hai Feng; Xiao-Long Li; Xue-Feng Liu; Hui-Chuan Sun; Zhao-You Tang
Journal:  Exp Hematol Oncol       Date:  2021-03-31

6.  Severe digital ischemia coexists with thrombocytopenia in malignancy-associated antiphospholipid syndrome: A case report and review of literature.

Authors:  Jia-Lei Chen; Xi Yu; Rong Luo; Ming Liu
Journal:  World J Clin Cases       Date:  2021-12-26       Impact factor: 1.337

Review 7.  Hepatocrinology.

Authors:  Sanjay Kalra; Saptarshi Bhattacharya; Pawan Rawal
Journal:  Med Sci (Basel)       Date:  2021-06-01

8.  Hepatocellular carcinoma-associated hypercholesterolemia: involvement of proprotein-convertase-subtilisin-kexin type-9 (PCSK9).

Authors:  Dipti Athavale; Surbhi Chouhan; Vimal Pandey; Shyamananda Singh Mayengbam; Snahlata Singh; Manoj Kumar Bhat
Journal:  Cancer Metab       Date:  2018-10-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.